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Abstract Inability to correctly repair DNA damage is
known to play a role in the development of breast cancer.
Single nucleotide polymorphisms (SNPs) of DNA repair
genes have been identified, which modify the DNA repair
capacity, which in turn may affect the risk of developing
breast cancer. To assess whether alterations in DNA repair
genes contribute to breast cancer, we genotyped 62 SNPs in
29 genes in 1,109 Cypriot women with breast cancer and
1,177 age-matched healthy controls. Five SNPs were
associated with breast cancer. SNPs rs13312840 and
rs769416 in the NBS1 gene were associated with a decrease
in breast cancer risk (OR TT vs. TC/CC = 0.58; 95% CI,
0.37–0.92; P = 0.019 and OR GG vs. GT/TT = 0.23, 95%
CI 0.06–0.85, P = 0.017, respectively). The variant allele
of MRE11A rs556477 was also associated with a reduced
risk of developing the disease (OR AA vs. AG/GG = 0.76;
95% CI, 0.64–0.91; P = 0.0022). MUS81 rs545500 and
PBOV1 rs6927706 SNPs were associated with an increased
risk of developing breast cancer (OR GG vs. GC/
CC = 1.21, 95% CI, 1.02–1.45; P = 0.031; OR AA vs.
AG/GG = 1.53, 95% CI, 1.07–2.18; P = 0.019, respec-
tively). Finally, haplotype-based tests identified significant
associations between specific haplotypes in MRE11A and
NBS1 genes and breast cancer risk. Further large-scale
studies are needed to confirm these results.
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Introduction
Breast cancer is the most common malignancy affecting
women worldwide, and it is the leading cancer in females
in Cyprus, with approximately 400 new cases diagnosed
annually [1]. In vitro studies have shown variability in
inter-individual DNA repair capacity and have demon-
strated that reduced ability to repair DNA is associated
with an increased risk for breast cancer [2–4]. It has also
been suggested that deficient DNA repair capacity predis-
poses to both familial and sporadic forms of breast cancer
[5–7].
Ten different genes that are involved in pathways crit-
ical to genomic integrity have been implicated in inherited
predisposition to breast cancer, including BRCA1, BRCA2,
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p53, PTEN, CHEK2, ATM, NBS1, RAD50, BRIP1 and
PALB2. The association of germline mutations in DNA
repair genes with an increased susceptibility to breast
cancer highlights the importance of these pathways in the
development of breast cancer [8].
The DNA repair pathway is clearly involved in familial
breast cancer. Thus, it was hypothesized that common
single nucleotide polymorphisms (SNPs) of genes involved
in the DNA repair pathway may influence breast cancer
risk. Many studies have investigated the role of SNPs in
DNA repair genes in relation to breast cancer and have
reported associations with breast cancer risk [9–12].
Analysis of members of the DNA repair pathway appears
to be a good rationale for identifying novel susceptibility loci.
In particular, genes which have a direct interaction with the
BRCA1 and BRCA2 genes are very good candidates.
Recently, two more susceptibility genes, namely BRIP1/
FANCJ and PALB2/FANCN, which interact with BRCA1 and
BRCA2 genes, respectively, have been identified [13, 14].
BRCA1 and BRCA2 participate in the biological response
to DNA damage that includes the activation of cell cycle
checkpoints and the recruitment of the DNA damage repair
machinery. Both BRCA1 and BRCA2 are implicated in
DNA repair by homologous recombination, and their pro-
teins have distinct roles in double-strand break repair [15].
Despite the progress that has been made in improving
our understanding of the functions of the BRCA1 protein, a
complete picture has not yet been attained. It has been
hypothesized that BRCA1 acts as a coordinator of the
various functions of DNA damage, recognition, response
and repair, and double-strand break repair. BRCA1 inter-
acts with many DNA repair proteins and protein complexes
including the RAD50-MRE11A-NBS1 (MRN) complex.
The proteins associated with BRCA1 are involved in
response to and in the repair of DNA damage in several
ways by acting as DNA damage sensors, signal transducers
and repair effectors. Hence, these proteins are instrumental
in the repair of DNA breakages and in the maintenance of
genomic integrity [16–18]. The exact role(s) of the BRCA2
protein also still remain(s) elusive. It has been demon-
strated that BRCA2 plays an important role in homologous
recombination, both in meiosis and in the repair of double-
strand breaks. Fewer proteins are known to interact with
BRCA2 compared to BRCA1 [19]. These include RAD51,
which mediates DNA repair via homologous recombina-
tion (HR) [15], and PALB2, which is required for BRCA2
nuclear localization and stability as well as for some of its
functions in HR and double-strand break repair [20].
Overall, BRCA1 and BRCA2 act in response to DNA
damage and participate in multi-protein complexes that are
involved in tumor suppression processes [17].
In this study, we hypothesized that germline variations in
genes encoding proteins that interact with BRCA1/2, are
potential candidates for modifying breast cancer risk in the
Cypriot population. Consequently, disturbances in the
interactions with BRCA1 and BRCA2 may prevent their
tumor suppression function(s) and consequently modify
inter-individual DNA repair capacity. As part of an ongoing
study we assessed genetic variation in 60 SNPs in 29 genes,
which interact with BRCA1 or BRCA2 genes and their
association with breast cancer in a case–control study of
Cypriot women. Furthermore, we investigated the role of
two additional SNPs in the PBOV1 (UROC28) and DBC2
genes that are both upregulated in breast cancer [21, 22].
Materials and methods
Study population
To investigate the associations between genetic factors and
breast cancer risk in the Cypriot population, we conducted
a population-based case–control study, with the acronym
MASTOS (Greek word for breast). The population of this
study are women participating in the MASTOS study.
Blood samples were collected between 2004 and 2006
from 1,109 female breast cancer patients diagnosed
between 40 and 70 years old and 1,177 age-matched
healthy controls. Participants were women who were pre-
viously diagnosed with breast cancer between January
1999 and December 2006. The majority of patients were
ascertained from the Bank of Cyprus Oncology Centre
which operates as a referral centre and offers treatment and
follow-up for 80–90% of all breast cancer cases diagnosed
in Cyprus. The rest of the patients were recruited at the
Oncology Departments of the Nicosia, Limassol, Larnaca
and Paphos district hospitals. The control group consisted
of healthy women who were participating in the National
program for breast cancer screening with the use of
mammography. Volunteers were enrolled in the study
during the same calendar period as the cases, from the four
district mammography screening centers that operate in
Cyprus. Eligible controls were women with no previous
history of breast cancer and who had a negative mam-
mography result. All study participants, both patients and
controls, were of Greek Cypriot Caucasian origin, thus
reducing any potential bias due to population stratification.
In addition, the study population was representative of the
whole island population and thus consisted of women, who
resided in all five districts of the country, minimizing
potential selection bias. The participation rate of cases and
controls was very high covering around 98% of eligible
cases and controls. In addition to blood samples, a risk
factor questionnaire, which included extensive demo-
graphic, epidemiologic and pathologic data, was obtained
from each participant through a standardized interview.
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Breast cancer cases were verified by reviewing histological
reports. The study was reviewed and approved by the
National Bioethics Committee of Cyprus. All participants
provided written informed consent.
Gene and SNP selection
Sixty-two SNPs in the ATF1, ATM, ATR, BARD1, BLM,
BRIP1, CHEK1, CHEK2, DDB2, DMC1, EME1, FANCA,
FANCC, FANCD2, FANCE, MLH1, MRE11A, MSH2,
MSH6, MUS81, NBS1, PALB2, PCNA, RFC1, RAD50,
RAD51C, RAD51L1, RAD52 and XPC genes were geno-
typed. The genetic variants were selected based on three
main criteria: (1) all SNPs chosen belong to genes that
interact with either BRCA1 or BRCA2; (2) the SNPs chosen
are either functional SNPs (based on potential protein
changes, evolutionary conservation and location in putative
functional regions [23–25] or (3) SNPs which were
reported by other groups to modify cancer risk [14, 26–32].
For MRE11A and RAD50, we genotyped the tagging SNPs
in Allen-Brady et al. [33], and for NBS1, we genotyped the
tagging SNPs in Lu et al. [32]. SNPs in the PBOV1 and
DBC2 genes were selected based on their minor allele
frequency (MAF) [0.05.
Genotyping
DNA was isolated from blood samples using standard
procedures (phenol–chloroform method). SNPs were gen-
otyped by matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF MS) of allele-
specific primer extension products (Mass Array, Sequenom
Inc., San Diego, CA, USA). Assay design was based on
published sequences retrieved from the National Center of
Biotechnology Information (NCBI) databases. A 34-plex
and a 28-plex multiplex assay were designed using the
Sequenom MassARRAY Assay Design software (version
3.0). SNPs were genotyped using Sequenom iPLEX
chemistry on a MALDI-TOF Compact Mass Spectrometer
(Sequenom Inc., San Diego, CA, USA).
Briefly, PCR reactions were carried out in a final volume
of 5 ll in standard 384-well plates. PCR was performed
with 5 ng of genomic DNA, 1 U of HotStarTaq DNA
polymerase (Qiagen, Hilden, Germany), 500 lmol of each
dNTP and 100 nmol of each PCR primer. PCR thermal
cycling was carried out in an ABI-9700 instrument
(Applied Biosystems, Foster City, CA, USA) for 15 min at
94C, followed by 44 cycles of 20 s at 94C, 30 s at 56C
and 60 s at 72C. Next, PCR products were treated with
0.5 U of shrimp alkaline phosphatase for 40 min at 37C to
dephosphorylate unincorporated dNTPs, followed by
enzyme inactivation for 5 min at 85C. After adjusting the
concentrations of the extension primers to equilibrate
signal-to-noise ratios, the post-PCR primer extension
reaction of the iPLEX gold assay was performed in a final
10 ll volume extension reaction containing 0.2 ul of ter-
mination mix, 0.0041 ll of iPLEX enzyme (Sequenom
Inc., San Diego, CA, USA) and 700–1,400 nM of exten-
sion primers. A two-step 200 short cycles program was
used for the iPLEX reaction: initial denaturation was for 30
s at 94C followed by five cycles of 5 s at 52C and 5 s at
80C. An additional 40 annealing and extension cycles
were then looped back to 5 s at 94C, 5 s at 52C and 5 s at
80C. Final extension was carried out at 72C for 3 min.
The iPLEX reaction products were desalted by diluting
samples with 16 ll of water and adding 6 mg of clean
resin. Following a quick centrifugation (3,200 g for 5 min),
reaction products were spotted on a 384-format Spectro-
Chip (Sequenom Inc., San Diego, CA, USA). Spectro-
CHIPs were processed in a MassARRAY Compact
Analyzer (Bruker Daltonics, Bremen, Germany) by Mass-
ARRAY Workstation (version 3.3) software (Sequenom
Inc., San Diego, CA, USA). Acquisition data were ana-
lyzed using MassARRAY TYPER 3.4 software (Sequenom
Inc., San Diego, CA, USA).
For quality control, 48 random samples were genotyped
in duplicate. Furthermore, ten samples were sequenced to
confirm genotype calls from the MALDI-TOF platform.
The genotype concordance rate between platforms was
99%. The order of the DNA samples on 384-well plates
was randomized in order to ensure the same study condi-
tions for samples from cases and controls. Genotyping call
rates ranged from 95 to 99%, and duplicate concordance
rates were higher than 99%. The SNP that had 20% missing
data was excluded from further analysis.
Data analysis
Hardy Weinberg equilibrium (HWE) was assessed in the
control samples by applying an exact test. The primary
tests of association were the univariate analyses between
each SNP and breast cancer. Genotype frequencies in cases
and controls were compared using the v2 test. The associ-
ation between breast cancer and each SNP was examined
using logistic regression with the SNP genotype tested
under models of complete dominance and recessive
inheritance as well as under the log-additive model after
adjusting for breast cancer risk factors including age (under
or over 55 years), menopause status (pre- or post-meno-
pausal), family history of breast cancer (first degree relative
with breast cancer) and use of hormone replacement ther-
apy. Statistical analysis was carried out using SNPStats, a
web-based application designed for analysis of association
studies [34].
Associations between breast cancer and common hap-
lotypes of the ATM, MRE11A and NBS1 genes were also
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investigated using SNPStats, which allows the estimation
of maximum likelihood estimates of haplotype frequencies
using the Expectation-Maximization (EM) algorithm.
Logistic regression was performed to test the association
between haplotypes and breast cancer risk. For assessing
the contribution of the MRE11A haplotypes in breast can-
cer risk, a haplotype tagging SNP genotyped previously
was also included in haplotype reconstruction [35]. Hap-
lotypes with a frequency of less than 1% were not con-
sidered further for analysis since they are likely to be a
result of rare recombination events.
Results
Table 1 shows the genotype frequency in cases and con-
trols for the 62 SNPs, of which the 61 were successfully
genotyped. Six SNPs (rs1800149, rs2706377, rs1800282,
rs7487683, rs3626, rs28908468) deviated from HWE in
controls (P \ 0.01) and were excluded from further anal-
ysis. Of the remaining 55 SNPs, 8 were monomorphic in
both groups. Significant differences in genotype frequen-
cies between breast cancer patients and controls were
observed in 5 of the 55 SNPs analyzed.
The associations of SNPs and breast cancer risk in
Cypriot women are shown in Table 2. Five of the 55 SNPs
were associated at a P value of less than 0.05. Three SNPs
were associated with a reduced risk for breast cancer while
the three remaining were associated with an increased
breast cancer risk. In detail, the variant allele of NBS1
rs13312840 (924 T[C) was associated with a reduced risk
of disease (OR TT vs. TC/CC = 0.58; 95% CI, 0.37 to
0.92; P = 0.019). Carriers of the NBS1 rs769416 rare allele
also had a reduced risk of breast cancer (OR GG vs. GT/
TT = 0.23, 95% CI 0.06–0.85, P = 0.017). Furthermore,
the variant allele of MRE11A rs556477 was associated with
a reduced risk of developing the disease (OR AA vs. AG/
GG = 0.76; 95% CI, 0.64–0.91; P = 0.0022). The variant
allele of MUS81 rs545500 was associated with an increased
risk of developing breast cancer (OR GG vs. GC/
CC = 1.21, 95% CI, 1.02–1.45; P = 0.031). In addition,
the rare allele of PBOV1 rs6927706 was also associated
with an increased risk of developing breast cancer (OR AA
vs. AG/GG = 1.53, 95% CI, 1.07–2.18; P = 0.019).
The NBS1 haplotype GGCGCAC (rs769416, rs769420,
rs13312840, rs1805794, rs6413508, rs12677527, rs1805
787), which contains the NBS1 rs13312840 C allele, to be
associated with a reduced breast cancer risk compared with
the most frequent haplotype GGTCCGC (OR = 0.62; 95%
CI = 0.39–0.97; P = 0.037). We also found a reduced risk
for breast cancer for a rare haplotype in NBS1 (OR = 0.42;
95% CI = 0.26–0.66; P = 2 9 10-4). In addition, the
MRE11A haplotype AGCG (rs556477, rs601341, rs1083
1234, rs1009456) is associated with a significantly increased
risk for breast cancer (OR = 1.32; 95% CI = 1.13–1.54;
P = 0.0004). None of the common ATM haplotypes were
associated with breast cancer (Table 3).
Discussion
Breast cancer is a complex polygenic disease. Published
data suggest that a proportion of breast cancer can be
explained by common low-penetrance alleles that increase
susceptibility [36]. High-penetrance mutations in genes
that are involved in DNA repair pathways such as BRCA1
and BRCA2 predispose to familial breast cancer [37, 38].
Previously our group characterized novel mutations in
these genes in Cypriot families [39, 40]. The importance of
common inherited variants in DNA repair genes in relation
to breast cancer risk is still being elucidated, but is cur-
rently receiving increased attention. Our group as part of an
ongoing investigation has studied genetic variation in DNA
repair genes in relation to breast cancer risk in the Cypriot
population and has reported a number of SNPs that modify
breast cancer risk [35, 41]. A number of large studies
which focused on the contribution of common SNPs in
DNA repair genes in breast cancer, using tagging SNP
approaches have also been completed [9, 42, 43]. In this
case–control study, we evaluated both functional as well as
tagging SNPs in DNA repair genes in relation to breast
cancer risk in Cypriot women.
We found that Cypriot women who carry NBS1
rs13312840 C and rs769416 T alleles have a reduced risk
of breast cancer. The NBS1 protein is involved in non-
homologous end-joining (NHEJ) pathway that repairs
DNA double-strand breaks (DSBs). The first step of this
pathway consists of the recognition of DSBs by the MRN
complex whose core contains the MRE11, RAD50 and
NBS1 proteins. NBS1 is the key regulator of this protein
complex [44, 45]. The NBS1 rs13312840 T[C SNP is
located on the 50 UTR (-1120) of the gene that is the
transcription factor GATA-1 binding site. The activation
domains of GATA-1 are capable of activating transcription
in mammalian cells through GATA motifs [46]. Our results
are in contrast to those of a recent study by Lu et al. who
found an increased risk for breast cancer in non-Hispanic
Caucasian women aged 55 or younger who were carriers of
the C allele [32]. Conflicting evidence for association may
be due to population-specific and/or age-specific differ-
ences. The protective effect of the NBS1 rs13312440 SNP
observed in our study could be attributed to the SNP itself
or to linkage disequilibrium with another variant.
To the best of our knowledge, this is the first study
investigating the role of NBS1 rs769416 SNP and breast
cancer risk. The rs769416 SNP causes an amino acid
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Table 1 Genotype frequencies in cases and controls for the 62 SNPs studied
Gene rs Number Controls Cases MAF HWE
AA Aa aa Total AA Aa aa Total Controls Cases Controls
ATF1 rs2230674 1,071 86 2 1,159 1,021 81 1 1,103 0.04 0.04 0.69
ATM rs1800057 1,087 85 2 1,174 1,015 85 0 1,100 0.04 0.04 0.68
rs2234997 1,153 4 1 1,158 1,093 10 0 1,103 0 0 0.01
rs2235000 1,160 1 0 1,161 1,102 2 0 1,104 0 0 1
rs3218688 979 2 0 981 926 0 0 926 0 0 1
rs3218695 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
rs3218708 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
rs4987945 1,169 1 0 1,170 1,100 1 0 1,101 0 0 1
ATR rs2227928 401 520 229 1,150 344 517 218 1,079 0.43 0.44 0.011
rs2229032 899 242 17 1,158 833 253 16 1,102 0.12 0.13 0.89
BARD1 rs2070094 466 551 156 1,173 461 485 159 1,105 0.37 0.36 0.75
rs2229571 341 580 249 1,170 316 540 241 1,097 0.46 0.47 0.95
rs3738888 1,150 7 0 1,157 1,099 4 0 1,103 0 0 1
BLM rs11852361 1,123 46 2 1,171 1,046 52 2 1,100 0.02 0.03 0.094
rs7167216 1,127 44 2 1,173 1,055 47 2 1,104 0.02 0.02 0.081
BRIP1 rs4986764 475 534 161 1,170 465 502 141 1,108 0.37 0.35 0.57
CHEK1 rs506504 1,064 105 5 1,174 986 116 2 1,104 0.05 0.05 0.19
CHEK2 rs17879961 1,158 0 0 1,158 1,101 1 0 1,102 0 0 1
DBC2 rs2241261 342 560 252 1,154 288 546 264 1,098 0.46 0.49 0.26
DDB2 rs830083 871 271 15 1,157 803 277 21 1,101 0.13 0.14 0.3
DMC1 rs2227914 1,146 3 0 1,149 1,099 1 1 1,101 0 0 1
EME1 rs12450550 918 221 24 1,163 838 239 23 1,100 0.12 0.13 0.021
FANCA rs1800282 978 149 19 1,146 883 189 16 1,088 0.08 0.1 \0.0001
rs7190823 573 476 113 1,162 541 462 98 1,101 0.3 0.3 0.33
rs9282681 1,096 51 0 1,147 1,065 42 2 1,109 0.02 0.02 1
FANCC rs1800364 1,159 1 0 1,160 1,104 1 0 1,105 0 0 1
FANCD2 rs2272125 787 346 38 1,171 710 346 43 1,099 0.18 0.2 1
FANCE rs9462088 1,051 115 4 1,170 990 106 4 1,100 0.05 0.05 0.56
MLH1 rs1800149 1,156 0 1 1,157 1,101 0 2 1,103 0 0 0.00043
rs2020872 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
rs2308317 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
rs1800734 494 496 137 1,127 446 505 136 1,087 0.34 0.36 0.47
MRE11A rs1009456 1,040 105 0 1,145 992 89 5 1,086 0.05 0.05 0.17
rs10831234 949 190 12 1151 899 193 6 1,098 0.09 0.09 0.48
rs556477 444 550 167 1,161 494 473 130 1,097 0.38 0.33 0.9
MSH2 rs2303428 929 217 18 1,164 870 211 16 1,097 0.11 0.11 0.22
MSH6 rs1042821 653 451 64 1,168 646 388 70 1,104 0.25 0.24 0.24
rs1800935 655 428 90 1,173 608 413 83 1,104 0.26 0.26 0.094
MUS81 rs545500 673 430 55 1,158 589 435 77 1,101 0.23 0.27 0.22
NBS1 rs1805787 548 483 104 1,135 549 447 103 1,099 0.3 0.3 0.94
rs1805794 543 502 109 1,154 511 497 96 1,104 0.31 0.31 0.68
rs6413508 1,167 6 1 1,174 1,097 4 0 1,101 0 0 0.012
rs769416 1,141 10 0 1,151 1,098 3 0 1,101 0 0 1
rs769420 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
rs12677527 546 505 115 1,166 512 497 96 1,105 0.32 0.31 0.95
rs13312840 1,122 55 0 1,177 1,075 32 1 1,108 0.02 0.02 1
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change (Gly to Lys) at codon 216 of the NBS1 gene. This
SNP is not located within one of the three functional
regions of the NBS1 protein, but it may have an alternative
splicing regulatory effect, based on the Functional Single
Nucleotide Polymorphism (F-SNP) database [47]. Our
result on the association of rs769416 SNP and breast
cancer needs to be interpreted with caution, since this is a
rare SNP in our population and the most likely explanation
for this association is chance.
Haplotype analysis with the combination of the seven
NBS1 SNPs showed that the frequency of the GGCGCAC
haplotype (rs769416, rs769420, rs13312840, rs1805794,
rs6413508, rs12677527, rs1805787) was lower in patients
than in controls (0.0147 vs. 0.0225; P = 0.035), suggesting
a protective effect. There was also evidence for a protective
effect of the rare pooled NBS1 haplotypes. This protective
effect is driven by the difference in frequencies of the
pooled rare haplotypes that conferred a low risk
(OR = 0.42) and had a combined frequency of 3.29% in
controls and 1.37% in patients. It is possible that these
pooled haplotypes are a marker for a single, rare, protective
mutation in the Cypriot population. There may be value in
sequencing this region in order to help identify the pro-
tective variant(s). Both these findings need to be replicated
in independent studies in order to confirm or refute this
effect.
Our data support the notion that MUS81 rs545500 C
allele carriers are at an increased risk for breast cancer.
Rs545500 is a non-synonymous SNP located in the coding
region of MUS81, a structure-specific DNA nuclease that
plays an important role in DNA repair by homologous
recombination [48]. This polymorphism results in an amino
acid change from a positively charged hydrophilic arginine
to an uncharged hydrophobic proline residue, which may
have an effect on the 3D structure or a protein–protein
binding interface of the MUS81 protein [25]. The role of
the MUS81 gene in breast cancer has not been investigated.
However, it was demonstrated that MUS81 homozygote
and heterozygote knockout mice have a predisposition to
develop cancer. Proper bialellic expression of MUS81 is
critical for the maintenance of genomic integrity and tumor
suppression [49]. Therefore, the rs545500 SNP could pre-
dispose individuals to breast cancer, but functional studies
need to be performed in order to identify the actual role of
this variant in carcinogenesis.
Our findings also suggest that the PBOV1 rs6927706
polymorphism may be a risk factor for breast cancer.
Rs6927706 is a non-synonymous SNP located in the cod-
ing region of PBOV1, a gene which is upregulated in
prostate, breast and bladder cancers [21]. The polymor-
phism results in an amino acid change at codon 73 from a
hydrophobic isoleucine to a hydrophilic threonine residue.
Bioinformatics analysis indicates that this SNP could be
involved in splicing regulation [47]. However, further work
is warranted since the exact roles of the PBOV1 protein as
well as its functional domains are not well known at
present.
Our current data suggest that the MRE11A rs556477 G
allele may be associated with a reduced breast cancer risk.
The MRE11A gene forms a complex with RAD50 and
NBS1 genes which is involved in the cellular response to
DNA double-strand breaks. Defects in the members of this
Table 1 continued
Gene rs Number Controls Cases MAF HWE
AA Aa aa Total AA Aa aa Total Controls Cases Controls
PALB2 rs45494092 1,170 1 0 1,171 1,097 4 0 1,101 0 0 1
rs45532440 1,035 120 4 1,159 972 126 4 1,102 0.06 0.06 0.77
rs45478192 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
rs45551636 1,076 92 2 1,170 1,010 92 2 1,104 0.04 0.04 1
PBOV1 rs6927706 1,083 63 1 1,147 1,017 83 2 1,102 0.03 0.04 0.61
PCNA rs3626 827 242 36 1,105 838 196 34 1,068 0.14 0.12 0.0012
RAD50 rs2299015 742 370 45 1,157 743 323 37 1,103 0.2 0.18 1
rs2522406 1,064 41 1 1,106 1,044 31 0 1,075 0.02 0.01 0.34
rs2706377 1,052 66 21 1,139 1,046 37 14 1,097 0.05 0.03 \0.0001
rs3187395 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
RAD51C rs28363317 1,164 6 0 1,170 1,095 6 0 1,101 0 0 1
RAD51L1 rs28908468 572 201 0 773 979 75 0 1,054 0.13 0.04 \0.0001
RAD52 rs7487683 1,135 35 3 1,173 1,072 33 0 1,105 0.02 0.01 0.0043
RFC1 rs2066791 1,177 0 0 1,177 1,109 0 0 1,109 0 0 Monomorphic
XPC rs2228000 673 402 64 1,139 653 379 65 1,097 0.23 0.23 0.68
rs2227999 1,040 128 4 1,172 963 138 4 1,105 0.06 0.07 1
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Table 2 Genotypic specific risk (OR and 95% CI)
Gene rs number Dominant OR (95% CI); P valuea Recessive OR (95% CI); P valuea Log-additive OR (95% CI); P valuea
ATF1 rs2230674 1.02 (0.74–1.42); 0.89 0.60 (0.05–7.34); 0.68 1.01 (0.73–1.40); 0.94
ATM rs1800057 1.10 (0.79–1.52); 0.57 – 1.07 (0.78–1.47); 0.69
rs2234997 2.31 (0.75–7.12); 0.13 – 1.83 (0.68–4.91); 0.23
rs4987945 1.27 (0.07–21.89); 0.87 – –
ATR rs2227928 1.14 (0.95–1.38); 0.15 1.04 (0.84–1.30); 0.71 1.07 (0.95–1.21); 0.25
rs2229032 1.09 (0.89–1.34); 0.42 1.01 (0.48–2.15); 0.97 1.07 (0.89–1.30); 0.45
BARD1 rs2070094 0.98 (0.82–1.17); 0.8 1.07 (0.83–1.37); 0.6 1.01 (0.89–1.14); 0.93
rs2229571 0.99 (0.82–1.20); 0.93 0.96 (0.78–1.18); 0.69 0.98 (0.87–1.11); 0.77
rs3738888 0.46 (0.13–1.66); 0.23 – –
BLM rs11852361 1.28 (0.85–1.95); 0.24 0.95 (0.13–7.12); 0.96 1.25 (0.84–1.85); 0.27
rs7167216 1.26 (0.82–1.94); 0.3 0.95 (0.13–7.14); 0.96 1.22 (0.81–1.84); 0.34
BRIP1 rs4986764 0.94 (0.79–1.12); 0.49 0.96(0.75–1.25); 0.78 0.96(0.85–1.09); 0.53
CHEK1 rs506504 1.19 (0.89–1.59); 0.24 0.48 (0.09–2.59); 0.37 1.15 (0.87–1.51); 0.34
DBC2 rs2241261 1.18 (0.97–1.43); 0.095 1.16 (0.94–1.43); 0.17 1.12 (0.99–1.27); 0.061
DDB2 rs830083 1.14(0.93–1.39); 0.2 1.51(0.74–3.07); 0.25 1.14(0.95–1.37); 0.15
DMC1 rs2227914 0.63 (0.09–4.39); 0.64 – 1.10 (0.25–4.73); 0.9
EME1 rs12450550 1.15 (0.94–1.42); 0.18 0.94 (0.52–1.72); 0.85 1.11 (0.92–1.33); 0.27
FANCA rs7190823 1.02 (0.86–1.22); 0.8 0.91 (0.68–1.23); 0.56 1.00 (0.87–1.14); 0.95
rs9282681 0.84 (0.54–1.30); 0.44 – 0.89 (0.58–1.35); 0.57
FANCC rs1800364 1.25 (0.07–21.55); 0.88 – –
FANCD2 rs2272125 1.12 (0.93–1.34); 0.24 1.08(0.68–1.72); 0.74 1.09 (0.93–1.28); 0.27
FANCE rs9462088 0.95 (0.71–1.26); 0.71 0.73 (0.15–3.53); 0.7 0.94 (0.71–1.24); 0.67
MLH1 rs1800734 1.09 (0.91–1.31); 0.33 1.01 (0.77–1.31); 0.96 1.05 (0.92–1.20); 0.46
MRE11A rs1009456 0.93 (0.68–1.26); 0.63 – 0.98 (0.73–1.32); 0.9
rs10831234 1.04 (0.83–1.31); 0.72 0.69 (0.25–1.93); 0.47 1.02 (0.82–1.26); 0.85
rs556477 0.76 (0.64–0.91); 0.0022 0.81 (0.62–1.05); 0.11 0.82 (0.72–0.93); 0.0027
MSH2 rs2303428 1.02 (0.82–1.26); 0.89 0.93 (0.45–1.89); 0.83 1.01 (0.83–1.22); 0.94
MSH6 rs1042821 0.85 (0.71–1.01); 0.066 1.23 (0.84–1.79); 0.29 0.92 (0.80–1.07); 0.27
rs1800935 1.09 (0.91–1.30); 0.34 1.07 (0.77–1.48); 0.69 1.07 (0.93–1.22); 0.36
MUS81 rs545500 1.21 (1.02–1.45); 0.031 1.43(0.98–2.08); 0.06 1.21(1.04–1.39); 0.012
NBS1 rs1805787 0.92 (0.77–1.10); 0.36 0.97 (0.72–1.31); 0.84 0.95 (0.83–1.08); 0.43
rs1805794 1.08 (0.91–1.28); 0.4 0.93 (0.69–1.26); 0.65 1.03 (0.90–1.18); 0.65
rs6413508 0.46 (0.13–1.66); 0.23 – 0.46 (0.14–1.50); 0.18
rs769416 0.23 (0.06–0.85); 0.017 – –
rs12677527 1.04 (0.88–1.24); 0.64 0.88 (0.65–1.19); 0.4 1.00 (0.87–1.14); 0.98
rs13312840 0.58 (0.37–0.92); 0.019 – 0.61 (0.39–0.95); 0.028
PALB2 rs45494092 3.75 (0.40–35.04); 0.2 – –
rs45532440 1.06 (0.81–1.40); 0.66 0.73 (0.18–3.04); 0.67 1.05 (0.80–1.36); 0.74
rs45551636 1.04 (0.76–1.43); 0.8 0.67 (0.09–4.89); 0.69 1.03 (0.76–1.4); 0.85
PBOV1 rs6927706 1.53 (1.07–2.18); 0.019 1.63(0.12–21.60); 0.71 1.51(1.06–2.13); 0.02
RAD50 rs2299015 0.89 (0.74–1.07); 0.21 0.90 (0.56–1.43); 0.65 0.91 (0.77–1.06); 0.22
rs2522406 0.80 (0.49–1.31); 0.37 – 0.78 (0.48–1.26); 0.31
rs3187395 0.32 (0.06–1.85); 0.19 – –
RAD51C rs28363317 0.93 (0.28–3.10); 0.91 – –
XPC rs2228000 1.01 (0.84–1.21); 0.91 0.96 (0.66–1.40); 0.85 1.00 (0.87–1.16); 0.99
rs2227999 1.12 (0.86–1.46); 0.42 1.10 (0.26–4.64); 0.42 1.11 (0.86–1.43); 0.43
Data in bold highlight the statically significant results
a Adjusted for age, menopause status, family history of breast cancer and use of hormone replacement therapy (HRT)
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tri-complex are linked to increased chromosomal instabil-
ity which leads to cancer [50]. The rs556477 common
variant is located in intron 15 of the MRE11A gene. The
rs556477 MAF is 40% in Caucasians as reported in NCBI’s
dbSNP database; the same as that observed in our popu-
lation. The functionality of this SNP is not clear. Using
the TFSEARCH webtool (http://www.cbrc.jp/research/
db/TFSEARCH.html), we searched for potential tran-
scription factors binding sites at this position. The
rs556477 SNP is located in a region that is a potential
transcription factor-binding site of activator protein 1
(AP-1), which plays a critical role in signal transduction
pathways in many cells. A recent study has shown that
inhibition of AP-1 transcription factors suppresses breast
cancer growth. Inhibitors that are capable of blocking AP-1
activation may be promising agents for the treatment and
prevention of breast cancer [51]. The reduced risk of breast
cancer for carriers of rs556477 SNP found in our study is in
contrast with the above finding since it is expected that the
creation of an AP-1 binding site will result in an increased
breast cancer risk. However, it must be taken into account
that the prediction that rs556477 A to G substitution results
in a gain of an AP-1 binding site is based on in silico
analysis and this remains to be proven by in vitro data.
Furthermore, the MRE11A rs556477 polymorphism may
not be causal, but could be in linkage disequilibrium with a
true protective variant.
In the current study, we present evidence for an
increased breast cancer risk for women carrying the
MRE11A AGCG (rs556477, rs601341, rs10831234,
rs1009456) haplotype. It is noteworthy that in a previous
study conducted by our group there was evidence for an
increased breast cancer risk for women homozygous for the
MRE11A rs601341 A allele [35]. The rs601341 A to G
substitution results in potential binding of ubiquitous tran-
scription factor Ying Yang 1 (YY1) that has a fundamental
role in normal biologic processes such as differentiation,
replication and cell proliferation. YY1 overexpression and/
or activation results in uncontrolled cellular proliferation,
resistance to apoptotic stimuli and tumorigenesis [52].
Given the intronic position of the two associated SNPs, it is
unlikely that these SNPs in and by themselves are disease
associated. Rather, in all likelihood, they are in linkage
disequilibrium with other variants that cause the associa-
tions observed.
Our study has several strengths, including a high par-
ticipation rate of eligible cases (98%) and a population
sample from a homogeneous ethnic background (all par-
ticipants are Greek Cypriots) thus reducing any potential
bias due to population stratification. In addition, our study
population (both cases and controls) was from all over the
country minimizing potential selection bias.
However, there were limitations in our study, one of
which is the possibility of survivor bias. This is one of the
Table 3 Estimated haplotype frequencies in cases and controls and haplotypic specific risks
Gene Haplotype Control freq Case freq OR [95% CI] v2 P value Global test P value
ATMa CCCCCTGC 0.92 0.9225 1.00 0.53
GCCCCTGC 0.0367 0.0349 0.96 (0.69–1.32) 0.8
CCCCGTGC 0.0376 0.0329 0.89 (0.34–1.23) 0.48
Rare 0.0057 0.0097 1.6 (0.72–3.57) 0.25
MRE11Ab GACG 0.3702 0.326 1.00 0.021
AGCG 0.2384 0.2752 1.32 (1.13–1.54) 4 3 1024
AACG 0.2478 0.255 1.17 (1.00–1.36) 0.044
AGTG 0.0864 0.0891 1.16 (0.93–1.45) 0.19
AGCT 0.0444 0.0438 1.12 (0.84–1.51) 0.44
Rare 0.0128 0.0109 0.98 (0.52–1.85) 0.95
NBS1c GGTCCGC 0.3705 0.3886 1.00 0.00019
GGTCCGG 0.2955 0.2925 0.94 (0.82–1.09) 0.44
GGTGCAC 0.2786 0.2905 0.99 (0.86–1.15) 0.92
GGCGCAC 0.0225 0.0147 0.62 (0.39–0.97) 0.037
Rare 0.0329 0.0137 0.42 (0.26–0.66) 2 3 1024
Data in bold highlight the statically significant results
a ATM haplotypes are arranged in the order of rs1800057, rs3218688, rs3218695, rs4987945, rs2230674, rs2234997, rs2235000, rs3218708
b MRE11A haplotypes are arranged in the order of rs556477, rs601341, rs10831234, rs1009456
c NBS1 haplotypes are arranged in the order of rs769416, rs769420, rs13312840, rs1805794, rs6413508, rs12677527, rs1805787
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known disadvantages of all retrospective case–control
studies. In our study, samples from breast cancer cases
were collected between 2004 and 2006 for cases diagnosed
between 1999 and 2006. Our study may therefore have
excluded a number of women with the most aggressive
form of breast cancer, diagnosed between 1999 and 2003.
It is possible that this could lead to ‘‘survivor bias’’ if
genotypes differ between those who succumb quickly
compared with longer-term breast cancer survivors.
The SNP selection for this study was based solely on
functionality and their position in genes interacting with
BRCA1/2 rather than allele frequency. As a result of this, a
number of monomorphic/low-polymorphic SNPs were
included in the study. It is noted that this is the first time
that these SNPs were studied in the Cypriot population, and
their allele frequencies were a priori unknown. Rare SNPs
can also contribute to disease risk [53]. However, our study
did not have sufficient power to detect such associations,
and the possibility that some of the low-polymorphic SNPs
studied contribute to breast cancer risk cannot be ruled out.
Another limitation of our study is that we did not con-
sider the possibility of gene–gene interactions or gene–
environment interactions. It is possible that the risks
observed are the result of interactions, but we have not
attempted to assess such effects, since the estimate of an
interaction effect will be unreliable because of the small
numbers available. Furthermore, we did not account for
multiple testing. When multiple comparisons are being
made, statistically significant associations may be identi-
fied by chance alone. Replication in independent, well-
powered studies is the gold standard of bona fide true
associations from chance findings. A Cypriot replication
set is not available to attempt to replicate the variants
identified, and replication will need to be performed in
other populations.
In conclusion, this study provides support for the
hypothesis that genetic variants in DNA repair genes
influence breast cancer risk and provides further evidence
for the polygenic model of breast cancer. However, large-
scale genetic epidemiologic studies are warranted to further
examine and corroborate the associations observed
between polymorphisms and breast cancer in multiethnic
groups. In addition, elucidation of the functional impact of
the breast cancer associated SNPs is needed in order to
provide further insights into their mechanistic effects on
risk.
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